Results 161 to 170 of about 9,026,423 (304)

Factors influencing American Board of Internal Medicine examination pass rates in US residency programs. [PDF]

Proc (Bayl Univ Med Cent)
Mehta A.
europepmc   +1 more source

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

Exploring the impact of burnout and mental health in women leadership on bank success. [PDF]

Medicine (Baltimore)
Liang WC, Khan I.
europepmc   +1 more source

Fluid and Neuroimaging Biomarkers in Microgliopathy Colony‐Stimulating Factor‐1 Receptor‐Related Disorders

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela, Madison Reeves, Karen Jansen‐West, Judith Dunmore, Yuping Song, Audrey Strongosky, Sunil Gandhi, Gilana Pikover, Matt Blurton‐Jones, Robert C. Spitale, Erik H. Middlebrooks, Leonard Petrucelli, Mercedes Prudencio, Zbigniew K. Wszolek   +13 more
wiley   +1 more source

The relationship between hospital case mix, academic affiliation, program size, and American Board of Internal Medicine examination pass rates. [PDF]

Proc (Bayl Univ Med Cent)
Abdulelah M, Khan MA, Nadeem S, Nassar K, Khoury ZS, Aldalki SK, Alshraiedeh M, Abdulelah H, Al-Ani H.   +8 more
europepmc   +1 more source

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
wiley   +1 more source

Response assessment of patients with locally advanced renal cell carcinoma receiving prior systemic therapy. [PDF]

BMC Cancer
Seifert KE, Dinkel H, Huberth L, Tiedje D, Gröticke J, Krabbe LM, Tepel F, Rahbar K, Bernemann C, Schrader AJ, Bögemann M, Janssen M, Schlack K, Heitplatz B.   +13 more
europepmc   +1 more source

On Size of HSA Governing Boards [PDF]

American Journal of Public Health, 1979
openaire   +1 more source

Exploratory Analysis of ELP1 Expression in Whole Blood From Patients With Familial Dysautonomia

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Familial dysautonomia (FD) is a hereditary neurodevelopmental disorder caused by aberrant splicing of the ELP1 gene, leading to a tissue‐specific reduction in ELP1 protein expression. Preclinical models indicate that increasing ELP1 levels can mitigate disease manifestations.
Alejandra González‐Duarte, Lucy Norcliffe‐Kaufmann, Maria Luisa Cotrina, Zenith Khan, Kaia Dalamo, Patricio Millar Vernetti, Matthew Lawless, Elisabetta Morini, Monica Salani, Marla Weetall, Jana Narasimhan, Agostino G. Rocha, Susan A. Slaugenhaupt, Horacio Kaufmann   +13 more
wiley   +1 more source

Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trial. [PDF]

BMJ Open Respir Res
Wuyts WA, Lancaster L, Maher TM, Ryerson CJ, Kreuter M, Corte TJ, Valenzuela C, Barnes CN, Lefebvre ÉA, Cosgrove GP, Flaherty KR, Richeldi L, Cottin V.   +12 more
europepmc   +1 more source